Achillion, Regulus chase shorter HCV regimens, but can they beat Gilead?
This article was originally published in Scrip
Executive Summary
Stock prices rose for Achillion Pharmaceuticals and fell for Regulus Therapeutics on 9 February as the companies revealed early clinical trial data that may support shorter durations of treatment for their hepatitis C virus (HCV) drugs, but HCV leader Gilead Sciences still could beat Achillion and Regulus to market with relatively fast-acting regimens.